Sponsors keep asking the wrong question. Whether to use FSP or full-service outsourcing feels like a strategic decision, but it is really a procurement reflex, and three regulatory shifts in the past year have made that reflex expensive.
In June 2026, FDA published a revised draft guidance clarifying how a single pivotal trial, with confirmatory evidence, can satisfy the substantial evidence standard for drug approval. China’s NMPA, under Announcement No. 86 of 2025, introduced a 30-working-day review pathway for qualifying innovative drugs. The European Biotech Act, proposed in December 2025, aims to simplify the regulatory path for cell and gene therapy trials across the EU. Each of these creates a narrower window to move: a sponsor who has locked in a delivery model before settling development strategy may find that model actively slowing the program down when a faster pathway opens up.
Fortrea’s argument, laid out in a new operational framework, is that the FSP-versus-full-service framing collapses under portfolio complexity. A single sponsor can be running a global Phase 3 that demands full-service scale, a regional study where embedded FSP staff make more sense, and an early-stage asset that needs specialist regulatory input and nothing else, simultaneously. Optimizing each of those against a single model preference means one of them is always misfit. The more useful sequence is to fix the development pathway first: what the asset needs from regulators, where execution risk is highest, which activities the sponsor must keep internal, and where the portfolio is likely to go in two or three years. The delivery model should follow from those answers, not precede them.
The practical consequence is that sponsors who treat outsourcing as a standing preference rather than a program-specific decision are building in friction before a trial starts. When the FDA single-trial pathway or the NMPA 30-day window becomes available, the question is whether the operating model can adapt quickly enough to use it. That adaptability, not the model label, is what the next outsourcing conversation needs to be about.
Source link: https://www.fortrea.com/insights/choosing-the-right-clinical-trial-outsourcing-model
Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.
